SG10201801179VA - Hemisulfate salt of 5,10-methylene-(6r)-tetrahydrofolic acid - Google Patents
Hemisulfate salt of 5,10-methylene-(6r)-tetrahydrofolic acidInfo
- Publication number
- SG10201801179VA SG10201801179VA SG10201801179VA SG10201801179VA SG10201801179VA SG 10201801179V A SG10201801179V A SG 10201801179VA SG 10201801179V A SG10201801179V A SG 10201801179VA SG 10201801179V A SG10201801179V A SG 10201801179VA SG 10201801179V A SG10201801179V A SG 10201801179VA
- Authority
- SG
- Singapore
- Prior art keywords
- methylene
- tetrahydrofolic acid
- hemisulfate salt
- hemisulfate
- salt
- Prior art date
Links
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
- C07D475/14—Benz [g] pteridines, e.g. riboflavin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13004050.4A EP2837631A1 (en) | 2013-08-14 | 2013-08-14 | New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201801179VA true SG10201801179VA (en) | 2018-03-28 |
Family
ID=48998397
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201601016PA SG11201601016PA (en) | 2013-08-14 | 2014-08-14 | Hemisulfate salt of 5,10-methylene-(6r)-tetrahydrofolic acid |
| SG10201801179VA SG10201801179VA (en) | 2013-08-14 | 2014-08-14 | Hemisulfate salt of 5,10-methylene-(6r)-tetrahydrofolic acid |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201601016PA SG11201601016PA (en) | 2013-08-14 | 2014-08-14 | Hemisulfate salt of 5,10-methylene-(6r)-tetrahydrofolic acid |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20160185787A1 (da) |
| EP (3) | EP2837631A1 (da) |
| JP (5) | JP6617104B2 (da) |
| KR (2) | KR102439605B1 (da) |
| CN (2) | CN108096200A (da) |
| AU (2) | AU2014307872B2 (da) |
| BR (2) | BR112016002770B1 (da) |
| CA (1) | CA2921178C (da) |
| CY (2) | CY1119694T1 (da) |
| DK (2) | DK3033344T3 (da) |
| EA (3) | EA202091271A3 (da) |
| ES (2) | ES2654474T3 (da) |
| HK (2) | HK1217018A1 (da) |
| HR (2) | HRP20171895T1 (da) |
| HU (2) | HUE054504T2 (da) |
| IL (2) | IL244069B (da) |
| LT (2) | LT3287460T (da) |
| MX (1) | MX360355B (da) |
| NO (1) | NO3033344T3 (da) |
| NZ (2) | NZ745811A (da) |
| PL (2) | PL3287460T3 (da) |
| PT (2) | PT3033344T (da) |
| RS (2) | RS56910B1 (da) |
| SG (2) | SG11201601016PA (da) |
| SI (2) | SI3033344T1 (da) |
| WO (1) | WO2015022407A1 (da) |
| ZA (1) | ZA201509204B (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2837631A1 (en) * | 2013-08-14 | 2015-02-18 | Merck & Cie | New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid |
| US10059710B2 (en) | 2016-02-17 | 2018-08-28 | Merck & Cie | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid |
| EP3446703A1 (en) * | 2017-08-24 | 2019-02-27 | Isofol Medical AB | 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy |
| EP3446704A1 (en) * | 2017-08-24 | 2019-02-27 | Isofol Medical AB | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
| EP3668516B1 (en) * | 2017-08-16 | 2021-09-22 | Merck Patent GmbH | Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid and a dicarboxylic acid |
| AU2019205861A1 (en) * | 2018-01-05 | 2020-08-06 | Isofol Medical Ab | Methods for treating colorectal and metastatic colorectal cancers |
| WO2021200365A1 (ja) * | 2020-03-30 | 2021-10-07 | 住友化学株式会社 | 積層体 |
| WO2023237483A1 (en) | 2022-06-08 | 2023-12-14 | Merck Patent Gmbh | Concentrated solutions comprising 5,10-methylene-(6r)-tetrahydrofolic acid |
| WO2023237482A1 (en) | 2022-06-08 | 2023-12-14 | Merck Patent Gmbh | Concentrated solutions comprising sodium 5,10-methylene-(6r)- tetrahydrofolate |
| WO2023237485A1 (en) | 2022-06-08 | 2023-12-14 | Merck Patent Gmbh | Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid |
| WO2023237484A1 (en) | 2022-06-08 | 2023-12-14 | Merck Patent Gmbh | Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate |
| WO2023237480A1 (en) | 2022-06-08 | 2023-12-14 | Merck Patent Gmbh | Stable pharmaceutical compositions comprising 5,10-methylene-(6r)-tetrahydrofolic acid and nacl |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2300505A (en) * | 1940-10-31 | 1942-11-03 | Bell Telephone Labor Inc | Selective system |
| WO1984004673A1 (en) | 1983-05-20 | 1984-12-06 | Bengt Gustavsson | A device for transferring a substance |
| DE3821875C1 (da) * | 1988-06-29 | 1990-02-15 | Eprova Ag, Forschungsinstitut, Schaffhausen, Ch | |
| CH682664A5 (en) * | 1991-10-15 | 1993-10-29 | Eprova Ag | Stable salts of 5,10-methylene tetrahydrofolate. |
| CH684644A5 (de) | 1992-07-13 | 1994-11-15 | Eprova Ag | 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen. |
| HU226998B1 (en) | 2000-11-23 | 2010-04-28 | Richter Gedeon Nyrt | Desloratadine hemisulphate, process for the preparation thereof and pharmaceutical compositions containing the same |
| CH696628A5 (de) | 2002-02-26 | 2007-08-31 | Eprova Ag | Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der |
| CH697021A5 (de) | 2003-06-26 | 2008-03-31 | Merck Eprova Ag | Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat. |
| CN101321518A (zh) * | 2005-12-02 | 2008-12-10 | 阿德文特克斯药物有限公司 | 5,10-亚甲基四氢叶酸盐的稳定药物组合物 |
| KR101148580B1 (ko) | 2006-12-21 | 2012-05-24 | 에프. 호프만-라 로슈 아게 | Ｍｇｌｕｒ5 수용체 길항제의 다형체 |
| JP5294968B2 (ja) | 2009-05-01 | 2013-09-18 | 三星ダイヤモンド工業株式会社 | スクライブヘッド及び該スクライブヘッドを用いたスクライブ装置 |
| US10849879B2 (en) * | 2011-10-19 | 2020-12-01 | Mercator Medsystems, Inc. | Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation |
| EP2837631A1 (en) * | 2013-08-14 | 2015-02-18 | Merck & Cie | New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid |
| EP2837766A1 (de) * | 2013-08-14 | 2015-02-18 | Sika Technology AG | Verfahren zum Ausfüllen einer Fuge mit einem Kleb- und/oder Dichtstoff sowie System zum Ausfüllen einer Fuge mit einem Kleb- und/oder Dichtstoff |
| JP6971761B2 (ja) * | 2017-10-11 | 2021-11-24 | 株式会社Ｉｈｉプラント | タンクの構築方法 |
-
2013
- 2013-08-14 EP EP13004050.4A patent/EP2837631A1/en not_active Withdrawn
-
2014
- 2014-08-14 SI SI201430529T patent/SI3033344T1/en unknown
- 2014-08-14 SG SG11201601016PA patent/SG11201601016PA/en unknown
- 2014-08-14 KR KR1020167006595A patent/KR102439605B1/ko active IP Right Grant
- 2014-08-14 BR BR112016002770-1A patent/BR112016002770B1/pt active IP Right Grant
- 2014-08-14 HU HUE17190279A patent/HUE054504T2/hu unknown
- 2014-08-14 US US14/912,328 patent/US20160185787A1/en not_active Abandoned
- 2014-08-14 HU HUE14758102A patent/HUE037615T2/hu unknown
- 2014-08-14 PT PT147581029T patent/PT3033344T/pt unknown
- 2014-08-14 RS RS20171337A patent/RS56910B1/sr unknown
- 2014-08-14 CN CN201810160334.3A patent/CN108096200A/zh active Pending
- 2014-08-14 LT LTEP17190279.4T patent/LT3287460T/lt unknown
- 2014-08-14 EP EP17190279.4A patent/EP3287460B1/en active Active
- 2014-08-14 EP EP14758102.9A patent/EP3033344B1/en active Active
- 2014-08-14 EA EA202091271A patent/EA202091271A3/ru unknown
- 2014-08-14 ES ES14758102.9T patent/ES2654474T3/es active Active
- 2014-08-14 SG SG10201801179VA patent/SG10201801179VA/en unknown
- 2014-08-14 SI SI201431825T patent/SI3287460T1/sl unknown
- 2014-08-14 DK DK14758102.9T patent/DK3033344T3/da active
- 2014-08-14 DK DK17190279.4T patent/DK3287460T3/da active
- 2014-08-14 BR BR122020002802-5A patent/BR122020002802B1/pt active IP Right Grant
- 2014-08-14 MX MX2016001834A patent/MX360355B/es active IP Right Grant
- 2014-08-14 EA EA201892729A patent/EA201892729A1/ru unknown
- 2014-08-14 ES ES17190279T patent/ES2871483T3/es active Active
- 2014-08-14 RS RS20210630A patent/RS61986B1/sr unknown
- 2014-08-14 PL PL17190279T patent/PL3287460T3/pl unknown
- 2014-08-14 LT LTEP14758102.9T patent/LT3033344T/lt unknown
- 2014-08-14 JP JP2016533926A patent/JP6617104B2/ja active Active
- 2014-08-14 PT PT171902794T patent/PT3287460T/pt unknown
- 2014-08-14 AU AU2014307872A patent/AU2014307872B2/en active Active
- 2014-08-14 WO PCT/EP2014/067447 patent/WO2015022407A1/en active Application Filing
- 2014-08-14 NZ NZ745811A patent/NZ745811A/en unknown
- 2014-08-14 KR KR1020217009189A patent/KR102410373B1/ko active IP Right Grant
- 2014-08-14 NO NO14758102A patent/NO3033344T3/no unknown
- 2014-08-14 NZ NZ71782514A patent/NZ717825A/en unknown
- 2014-08-14 CA CA2921178A patent/CA2921178C/en active Active
- 2014-08-14 EA EA201600172A patent/EA032179B1/ru not_active IP Right Cessation
- 2014-08-14 CN CN201480044477.8A patent/CN105452250B/zh active Active
- 2014-08-14 PL PL14758102T patent/PL3033344T3/pl unknown
-
2015
- 2015-12-17 ZA ZA2015/09204A patent/ZA201509204B/en unknown
-
2016
- 2016-02-11 IL IL244069A patent/IL244069B/en active IP Right Grant
- 2016-04-29 HK HK16104972.6A patent/HK1217018A1/zh unknown
-
2017
- 2017-12-05 HR HRP20171895TT patent/HRP20171895T1/hr unknown
- 2017-12-12 CY CY20171101298T patent/CY1119694T1/el unknown
-
2018
- 2018-09-03 JP JP2018164332A patent/JP6735321B2/ja active Active
- 2018-11-29 HK HK18115320.9A patent/HK1256262A1/zh unknown
- 2018-12-06 US US16/212,056 patent/US20190106431A1/en not_active Abandoned
- 2018-12-13 AU AU2018278943A patent/AU2018278943B2/en active Active
-
2019
- 2019-04-02 JP JP2019070293A patent/JP6764501B2/ja active Active
- 2019-09-08 IL IL269170A patent/IL269170B/en active IP Right Grant
-
2020
- 2020-05-11 JP JP2020083208A patent/JP7396960B2/ja active Active
-
2021
- 2021-04-27 CY CY20211100364T patent/CY1124076T1/el unknown
- 2021-05-12 HR HRP20210743TT patent/HRP20210743T1/hr unknown
- 2021-10-08 US US17/496,939 patent/US12122783B2/en active Active
- 2021-11-11 JP JP2021183793A patent/JP2022024035A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269170B (en) | The hemisulfate salt of tetrahydrofolic acid 5, 10 methylene (6r) | |
| IL263653A (en) | History of azabenzimidazole as PI3K inhibitors in the cell | |
| IL247901A0 (en) | Additional salts of (s)-2-(1-(6-amino-5-cyanopyrimidine-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1 ,2,4]triazine-5-carbonitrile | |
| HRP20170919T1 (hr) | Novi derivati pirazola | |
| SG11201600062RA (en) | Pyrimidine derivatives as kinase inhibitors | |
| IL245660B (en) | History of aminopyridines as tam family kinase inhibitors | |
| EP2981535B8 (en) | Urea derivatives useful as kinase inhibitors | |
| EP3016953A4 (en) | Purinone compounds as kinase inhibitors | |
| ZA201808014B (en) | Adenine derivatives as protein kinase inhibitors | |
| EP3024427A4 (en) | Derivatives of 2,2,6-trimethylcyclohexane-carboxylate | |
| GB2520791B (en) | Method of producing derivatives of 1,3,5-triarylbenzene | |
| SG11201601135QA (en) | 3-substituted cyclopentylamine derivatives |